Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen

British Journal of Clinical Pharmacology

Volumn 78, Issue 3, 2014, Pages 572-586

  Ter Heine, Rob ^a   Binkhorst, Lisette ^b   De Graan, Anne Joy M ^b   De Bruijn, Peter ^b   Beijnen, Jos H ^c,d   Mathijssen, Ron H J ^b   Huitema, Alwin D R ^c  

^a MEANDER MEDICAL CENTER   (Netherlands)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

CYP2D6; CYP3A; endoxifen; metabolic phenotype; nonmem; tamoxifen

Indexed keywords

ALPELISIB; ANTINEOPLASTIC AGENT; BYL 719; PHOSPHATIDYLINOSITIDE 3 KINASE ANTAGONIST; UNCLASSIFIED DRUG; 4-HYDROXY-N-DESMETHYLTAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DEXTROMETHORPHAN; PRODRUG; TAMOXIFEN;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER PATIENT; COLORECTAL CANCER; COMPARTMENT MODEL; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFICACY; DRUG EXPOSURE; EVENING DOSAGE; FEMALE; HEAD AND NECK CANCER; HUMAN; IC 50; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; VOLUME OF DISTRIBUTION; ANALOGS AND DERIVATIVES; BAYES THEOREM; BIOLOGICAL MODEL; BREAST NEOPLASMS; CLINICAL TRIAL (TOPIC); DRUG MONITORING; METABOLISM; MIDDLE AGED; NONLINEAR SYSTEM; PHENOTYPE; PROCEDURES; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BAYES THEOREM; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; DEXTROMETHORPHAN; DRUG MONITORING; FEMALE; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; PHENOTYPE; PRODRUGS; TAMOXIFEN; YOUNG ADULT;

EID: 84906519403     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12388     Document Type: Article

References (46)

1. Murdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, Fasching PA, Fehm T, Eichelbaum M, Schwab M, Brauch H,. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 2011; 89: 708-717.
2. Coezy E, Borgna JL, Rochefort H,. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 1982; 42: 317-323. (Pubitemid 12207285)
3. Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, Nikoloff DM, Hillman G, Fontecha MR, Lawrence HJ, Parker BA, Wu AH, Pierce JP,. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 2011; 89: 718-725.
4. Gong IY, Teft WA, Ly J, Chen YH, Alicke B, Kim RB, Choo EF,. Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts. Breast Cancer Res Treat 2013; 19: 61-69.
5. Newman WG, Hadfield KD, Latif A, Roberts SA, Shenton A, McHague C, Lalloo F, Howell S, Evans DG,. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin Cancer Res 2008; 14: 5913-5918.
6. Desta Z, Ward BA, Soukhova NV, Flockhart DA,. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004; 310: 1062-1075. (Pubitemid 39108928)
7. Hoskins JM, Carey LA, McLeod HL,. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 2009; 9: 576-586.
8. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM, Wu L, Hillman G, Hayes DF, Stearns V, Flockhart DA,. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006; 80: 61-74. (Pubitemid 43946844)
9. Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM, Fritcher EG, Nibbe AM, Desta Z, Nguyen A, Flockhart DA, Perez EA, Ingle JN,. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007; 101: 113-121. (Pubitemid 47555336)
10. Lee HS, Goh BC, Fan L, Khoo YM, Wang L, Lim R, Ong AB, Chua C,. Phenotyping CYP3A using midazolam in cancer and non-cancer Asian patients. Br J Clin Pharmacol 2003; 55: 270-277. (Pubitemid 36390757)
11. Kharasch ED, Jubert C, Senn T, Bowdle TA, Thummel KE,. Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. J Clin Pharmacol 1999; 39: 664-669.
12. Binkhorst L, van Gelder T, Mathijssen RH,. Individualization of tamoxifen treatment for breast carcinoma. Clin Pharmacol Ther 2012; 92: 431-433.
13. Irvin WJ, Jr, Walko CM, Weck KE, Ibrahim JG, Chiu WK, Dees EC, Moore SG, Olajide OA, Graham ML, Canale ST, Raab RE, Corso SW, Peppercorn JM, Anderson SM, Friedman KJ, Ogburn ET, Desta Z, Flockhart DA, McLeod HL, Evans JP, Carey LA,. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol 2011; 29: 3232-3239.
14. Brauch H, Schroth W, Goetz MP, Murdter TE, Winter S, Ingle JN, Schwab M, Eichelbaum M,. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol 2013; 31: 176-180.
15. Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J, Dowsett M,. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 2012; 104: 452-460.
16. Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'orto P, Biasi MO, Thurlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G,. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 2012; 104: 441-451.
17. Rae JM, Regan M, Leyland-Jones B, Hayes DF, Dowsett M,. CYP2D6 genotype should not be used for deciding about tamoxifen therapy in postmenopausal breast cancer. J Clin Oncol 2013; 31: 2753-2755.
18. Rae JM, Regan MM, Thibert JN, Gersch C, Thomas D, Leyland-Jones B, Viale G, Pusztai L, Hayes DF, Skaar T, Van PC,. Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. J Natl Cancer Inst 2013; 19: 1332-1334.
19. Jacqz-Aigrain E, Funck-Brentano C, Cresteil T,. CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 1993; 3: 197-204. (Pubitemid 23265487)
20. Yu A, Haining RL,. Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? Drug Metab Dispos. 2001; 29: 1514-1520. (Pubitemid 33000701)
21. Jones DR, Gorski JC, Hamman MA, Hall SD,. Quantification of dextromethorphan and metabolites: a dual phenotypic marker for cytochrome P450 3A4/5 and 2D6 activity. J Chromatogr B Biomed Appl 1996; 678: 105-111. (Pubitemid 26114746)
22. Wieling J, Tamminga WJ, Sakiman EP, Oosterhuis B, Wemer J, Jonkman JH,. Evaluation of analytical and clinical performance of a dual-probe phenotyping method for CYP2D6 polymorphism and CYP3A4 activity screening. Ther Drug Monit 2000; 22: 486-496. (Pubitemid 30622124)
23. Min DI, Ku YM, Vichiendilokkul A, Fleckenstein LL,. A urine metabolic ratio of dextromethorphan and 3-methoxymorphinan as a probe for CYP3A activity and prediction of cyclosporine clearance in healthy volunteers. Pharmacotherapy 1999; 19: 753-759. (Pubitemid 29277976)
24. Ducharme J, Abdullah S, Wainer IW,. Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. J Chromatogr B Biomed Appl 1996; 678: 113-128. (Pubitemid 26114747)
25. Funck-Brentano C, Boelle PY, Verstuyft C, Bornert C, Becquemont L, Poirier JM,. Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects. Eur J Clin Pharmacol 2005; 61: 821-829. (Pubitemid 41720270)
26. de Graan AJ, Teunissen SF, de Vos FY, Loos WJ, van Schaik RH, de Jongh FE, de Vos AI, van Alphen RJ, van der Holt. B, Verweij J, Seynaeve C, Beijnen JH, Mathijssen RH., Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. J Clin Oncol 2011; 29: 3240-3246.
27. Hutson PR, Love RR, Havighurst TC, Rogers E, Cleary JF,. Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer. Clin Cancer Res 2005; 11: 8722-8727. (Pubitemid 43005922)
28. Abduljalil K, Frank D, Gaedigk A, Klaassen T, Tomalik-Scharte D, Jetter A, Jaehde U, Kirchheiner J, Fuhr U,. Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan. Clin Pharmacol Ther 2010; 88: 643-651.
29. Moghadamnia AA, Rostami-Hodjegan A, Bdul-Manap R, Wright CE, Morice AH, Tucker GT,. Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition. Br J Clin Pharmacol 2003; 56: 57-67. (Pubitemid 36886489)
30. Loos WJ, de Graan AJ, de Bruijn. P, van Schaik RH, van Fessem MA, Lam MH, Mathijssen RH, Wiemer EA., Simultaneous quantification of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry. J Pharm Biomed Anal 2011; 54: 387-394.
31. Teunissen SF, Jager NG, Rosing H, Schinkel AH, Schellens JH, Beijnen JH,. Development and validation of a quantitative assay for the determination of tamoxifen and its five main phase I metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879: 1677-1685.
32. Keizer RJ, van Benten. M, Beijnen JH, Schellens JH, Huitema AD., Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed 2011; 101: 72-79.
33. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO,. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 2011; 13: 143-151.
34. Comets E, Brendel K, Mentre F,. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 2008; 90: 154-166.
35. Jonsson EN, Karlsson MO,. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58: 51-64. (Pubitemid 29049052)
36. Lindbom L, Ribbing J, Jonsson EN,. Perl-speaks-NONMEM (PsN)- A Perl module for NONMEM related programming. Comput Methods Programs Biomed 2004; 75: 85-94. (Pubitemid 38798039)
37. Levi M, Dempsey DA, Benowitz NL, Sheiner LB,. Population pharmacokinetics of nicotine and its metabolites I. Model development. J Pharmacokinet Pharmacodyn 2007; 34: 5-21. (Pubitemid 46122545)
38. Levi M, Dempsey DA, Benowitz NL, Sheiner LB,. Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples II. Model application. J Pharmacokinet Pharmacodyn 2007; 34: 23-34. (Pubitemid 46122546)
39. Hendrickson HP, Gurley BJ, Wessinger WD,. Determination of dextromethorphan and its metabolites in rat serum by liquid-liquid extraction and liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 788: 261-268. (Pubitemid 36428529)
40. Shivva V, Korell J, Tucker IG, Duffull SB,. An approach for identifiability of population pharmacokinetic-pharmacodynamic models. CPT Pharmacometr Syst Pharmacol 2013; 19: e49. doi: 10.1038/psp.2013.25.
41. Evans ND, Godfrey KR, Chapman MJ, Chappell MJ, Aarons L, Duffull SB,. An identifiability analysis of a parent-metabolite pharmacokinetic model for ivabradine. J Pharmacokinet Pharmacodyn 2001; 28: 93-105.
42. Ahmad A, Shahabuddin S, Sheikh S, Kale P, Krishnappa M, Rane RC, Ahmad I,. Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects. Clin Pharmacol Ther 2010; 88: 814-817.
43. Opdam FL, Dezentje VO, den Hartigh. J, Modak AS, Vree R, Batman E, Smorenburg CH, Nortier JW, Gelderblom H, Guchelaar HJ., The use of the (13)C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels. Cancer Chemother Pharmacol 2013; 71: 593-601.
44. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC,. The human intestinal cytochrome P450 'pie'. Drug Metab Dispos 2006; 34: 880-886.
45. Dickschen K, Willmann S, Thelen K, Lippert J, Hempel G, Eissing T,. Physiologically based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balance. Front Pharmacol 2012; 3: 1-15.
46. Lien EA, Anker G, Ueland PM,. Pharmacokinetics of tamoxifen in premenopausal and postmenopausal women with breast cancer. J Steroid Biochem Mol Biol 1995; 55: 229-231.